Hepatocellular carcinoma in the absence of liver cirr r rhosis in a treated hepatir r tis C virus patient
To the Editor: A 65-year-old male patient was referred to King Faisal Hospital and Research Centre after he presented with jaundice, fever, abdominal discomfort and bio-chemical evidence of chronic hepa-titis C virus (HCV) hepatitis with no clinical or histological evidence of cirrhosis. HCV polymerase chain reaction (PCR) was positive and HCV quantitation was 4682 cop-ies/mL. Liver function test (LFT) results were ALT 225 IU/L (refer-ence range, 5-60 IU/L), AST 104 IU/L (reference range, 5-43 IU/L), total bilirubin 20 µml/L (reference range, 5.1-17.0 µmol/L), INR 1.2 (reference range, 0.9-1.1), and al-bumin 38 g/L (reference range, 35-50 g/L). Liver biopsy showed chronic hepatitis grade II, stage II portal fibrosis and no evidence of cirrhosis. Alpha-fetoprotein was 6 µgm/L. The patient completed a full year of combination therapy of pegulated interferon 3 million units subcutaneously 3 times/week with ribavirin 1000 mg orally daily and achieved a negative viral PCR with normal LFTs. He had 3 years of fol-low-up with a sustained virological response (sustained loss of detect-able virus in response to antiviral therapy) and was then discharged from our clinic and instructed to follow-up at his local hospital. A CT scan at discharge showed no evidence of cancer (image not avail-able). Two years later he was re-ferred back from his local hospital with a huge right hypochondrial mass associated with pain but no jaundice, fever or weight loss. The mass was about 10 cm in diameter, difficult to separate from the liver, ill-defined, lobulated and hard. Basic tests, including CBC and re--nal profile were normal. ALT 27 IU/L (reference range, 5-60 IU/L), AST 35 IU/L (reference range, 5-43 IU/L), ALP 75 IU/L (reference range, 30-120 IU/L), total bilirubin 14 µml/L (reference range, 5.1-17.0 µmol/L), INR 1.0 (reference range, 0.9-1.1), and albumin 42 g/L (reference range, 35-50 g/L). AFP was 2.3 µgm/L and carcinoembry-onic antigen (CEA) was 2.1 µgm/L. Ultrasound of the abdomen showed a huge liver mass (8cm×11cm) and the right portal vein branch was not visualized distally. CT of the abdomen showed the same mass at segment 5 and 8 which was consis-tent with hepatocellullar carcinoma (HCC) showing the classical tri-phasic pattern, i.e., heterogenous enhancement in the arterial phase, but early rapid washout in the por-tal-venous phase leaving the HCC lesion hypo-dense compared to the surrounding normal tissue ( Figure  1 ). The patient underwent surgical removal of both segments (5 and 8). Histopathology of the mass con-firmed the diagnosis of HCC. H&E stain showed the HCC pseudoglan-dular and trabecular pattern ( Figure  2 ) and extensive lymphovasculer in-vasion. Immunohistochemical stain for CD34 was positive and showed wrapping of the tumor cluster by endothelial cells. The rest of the non-neoplastic livers showed only mild steatosis and no cirrhosis at all (Trichrome stain) ( Figure 3) .
HCC, which arises from the hepatocytes, is the most common type of primary liver malignancy. It commonly arises in cirrhotic liver. Chronic HCV is a leading cause of cirrhosis worldwide. 1 AFP levels may be normal in more than one third of patients. 2 In our patient, despite having no evidence of cir-rhosis and achieving a sustained viral response for 5 years after treat-ment with combination therapy, he developed HCC. In addition, 
RefeReNces
he had a negative AFP screening test on more than one occasion. Okanoue et al 3 conducted a longterm follow-up study of 1246 cases of chronic HCV who received stan-dard pegulated interferon therapy to study the effect of interferon on development of HCC. Interferon lowered the rate of HCC develop-ment in both sustained and tran-sient biochemical responders com-pared to none responders. but did not prevent HCC. In another study by Omata et al 4 that examined the role of interferon treatment on pre-vention of HCC in chronic HCV patients, development of HCC was strongly associated with stage of liv-er fibrosis, age and gender. The risk was reduced to 1/5 by interferon, but not prevented among sustained responders compared to untreated patients. Patients at risk of devel-oping HCC should be offered sur-veillance ultrasound at 3-4 monthly intervals (based on tumor doubling time). 5 A negative initial screening for HCC does not mean that HCC is absent, but only that the tests are insufficiently sensitive. An abnor-mal screening test requires a tripha-sic CT or MRI or both, and failure to confirm the diagnosis requires enhanced CT at an interval of 3-4 months. 5 We found only one case in the literture of HCC in the absence of cirrhosis, but the patient had an ad-ditional risk factor, which was por-phyria cutanea tarda. 6 An epidemi-ological study reported HCC with HCV in the absence of cirrhosis in 7 patients, but 5 had coinfection with HBV and the rest had evidence of high alcohol intake (alcohol intake >80 g/day). 7 To our knowldge, our case is the first in a patient with no co-infection and no evidence of oth-er risk factors for HCC apart from HCV infection. Our case suggests that HCC can develop years later in patients with HCV who were
